Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.
  • Posted by Dr Allison Fleetwood
  • November 11, 2014
  • Articles

A guide to measuring and tracking brand KPIs

A guide to measuring and tracking brand KPIs

Dr Allison Fleetwood, Director of Therapy Watch, alongside Associate Director Jennifer Redfearn, recently delivered a workshop on measuring and tracking brand KPIs as part of the BHBIA training programme (www.bhbia.org.uk).

With tighter market research budgets and new products under pressure to do well in a very short period of time, there’s very little margin for error. To succeed, market researchers must achieve internal alignment, clarity around critical success factors, and full visibility of launch performance.

read more »

  • Posted by Julie Denny
  • July 21, 2014
  • Webinars

Webcast: Biosimilars: Friend or Foe to Healthcare?

Webcast: Biosimilars: Friend or Foe to Healthcare?

Understanding the opportunities for biosimilars and the threats to innovator biologics

Referencing recent findings from our Therapy Watch syndicated study in RA, this webinar investigates physicians' perceptions of the biosimilars market. Therapy Watch Director Allison Fleetwood and Access Partnership Director Shrinivas Rao Mukku interview a major US payer, who offers expert opinion on the opportunities for biosimilars in the US market, the possible threats to originator brands, and consider what companies entering the market need to do to effectively launch their follow-on biologic.
 

read more »

  • Posted by Julie Denny
  • June 4, 2014
  • Events

EULAR Annual European Congress of Rheumatology 2014

EULAR Annual European Congress of Rheumatology 2014

Join us at EULAR Congress 2014 in Paris on Friday 13th June at 11:45 - 13:30

We are delighted to be attending and presenting at this year’s EULAR Annual European Congress of Rheumatology in Paris. The EULAR annual congress is a major event in the field of rheumatology and a great forum for scientific (both clinical and basic) educational and social exchange between healthcare professionals involved in rheumatology, patient organisations and the pharmaceutical industry. Representing the Research Partnership and more specifically, Therapy Watch, will be Director Allison Fleetwood and Associate Director Laurent Chanroux who work at our London headquarters.

read more »

Biosimilars: Friend or Foe?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000.

read more »

  • Posted by Julie Denny
  • February 21, 2014
  • News

Biosimilars: Friend or foe to healthcare?

Biosimilars: Friend or foe to healthcare?

Our recent article in February’s Pharma Market Europe and our latest Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000. 

read more »